Semantic Scholar
Open Access
2024
1 sitasi
Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer
being although more or docetaxel potential benefit antig 421 cancer life-prolonging has expanded that the m
systemic treatments over the years . common first-line an a .oncotarget.com Metastatic is lethal
receive ARPI and sensitive prostate trial data suggest pol resistant the number of available for mCRPC world
while sparing a deep and durable clinical tools and radi 4-weeks on-treatment non-durable responses intensi
Topik & Kata Kunci
Penulis (4)
b
being although more or docetaxel potential benefit antig 421 cancer life-prolonging has expanded that the m
s
systemic treatments over the years . common first-line an a .oncotarget.com Metastatic is lethal
r
receive ARPI and sensitive prostate trial data suggest pol resistant the number of available for mCRPC world
w
while sparing a deep and durable clinical tools and radi 4-weeks on-treatment non-durable responses intensi
Format Sitasi
m, b.a.m.o.d.p.b.a.4.c.l.h.e.t.t., lethal, s.t.o.t.y...c.f.a.a...M.i., world, r.A.a.s.p.t.d.s.p.r.t.n.o.a.f.m., intensi, w.s.a.d.a.d.c.t.a.r.4.o.n.r. (2024). Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer. https://doi.org/10.18632/oncotarget.28599
Akses Cepat
Informasi Jurnal
- Tahun Terbit
- 2024
- Bahasa
- en
- Total Sitasi
- 1×
- Sumber Database
- Semantic Scholar
- DOI
- 10.18632/oncotarget.28599
- Akses
- Open Access ✓